12:01 EST Sarepta (SRPT) falls 10% to $21.37 after reporting preliminary Q4 revenue
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta submits clinical trial application for study SRP-1005-101 to Medsafe
- Sarepta Therapeutics Extends Debt Maturities with New Notes
- HHS adds Duchenne muscular dystrophy to recommended screening panel
- Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts
- Sarepta put volume heavy and directionally bearish